{"title":"戊型肝炎病毒感染。","authors":"Basavraj S Nagoba, Abhijit S Rayate","doi":"10.5501/wjv.v13.i2.90951","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are required.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 2","pages":"90951"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229837/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hepatitis E virus infections.\",\"authors\":\"Basavraj S Nagoba, Abhijit S Rayate\",\"doi\":\"10.5501/wjv.v13.i2.90951\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are required.</p>\",\"PeriodicalId\":61903,\"journal\":{\"name\":\"世界病毒学杂志(英文版)\",\"volume\":\"13 2\",\"pages\":\"90951\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229837/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"世界病毒学杂志(英文版)\",\"FirstCategoryId\":\"1089\",\"ListUrlMain\":\"https://doi.org/10.5501/wjv.v13.i2.90951\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界病毒学杂志(英文版)","FirstCategoryId":"1089","ListUrlMain":"https://doi.org/10.5501/wjv.v13.i2.90951","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
戊型肝炎病毒(HEV)感染目前在全球流行。大多数急性感染患者都能顺利康复。爆发和零星病例,尤其是高危人群中的爆发和零星病例正日益增多。有妊娠和原有慢性肝病等危险因素的患者会出现或迅速发展为重症。移植后患者的免疫抑制也是一个风险因素。当务之急是进行经美国食品及药物管理局批准的标准化诊断检测。需要开展进一步研究,以制定基于指南的治疗方案和 HEV 爆发准备工作,从而降低全球发病率、死亡率和医疗负担。需要制定筛查捐献者和移植病例的政策。
Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are required.